[go: up one dir, main page]

CA2699908A1 - Compositions contenant du resveratrol destinees a moduler la concentration ou l'activite d'un produit genique - Google Patents

Compositions contenant du resveratrol destinees a moduler la concentration ou l'activite d'un produit genique Download PDF

Info

Publication number
CA2699908A1
CA2699908A1 CA2699908A CA2699908A CA2699908A1 CA 2699908 A1 CA2699908 A1 CA 2699908A1 CA 2699908 A CA2699908 A CA 2699908A CA 2699908 A CA2699908 A CA 2699908A CA 2699908 A1 CA2699908 A1 CA 2699908A1
Authority
CA
Canada
Prior art keywords
resveratrol
containing composition
composition
product
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2699908A
Other languages
English (en)
Other versions
CA2699908C (fr
Inventor
William F. Sardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resveratrol Partners LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2699908A1 publication Critical patent/CA2699908A1/fr
Application granted granted Critical
Publication of CA2699908C publication Critical patent/CA2699908C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2699908A 2007-09-20 2008-09-17 Compositions contenant du resveratrol destinees a moduler la concentration ou l'activite d'un produit genique Expired - Fee Related CA2699908C (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US97381707P 2007-09-20 2007-09-20
US60/973,817 2007-09-20
US2323408P 2008-01-24 2008-01-24
US2322708P 2008-01-24 2008-01-24
US2323008P 2008-01-24 2008-01-24
US61/023,230 2008-01-24
US61/023,234 2008-01-24
US61/023,227 2008-01-24
US4874708P 2008-04-29 2008-04-29
US4875608P 2008-04-29 2008-04-29
US4876908P 2008-04-29 2008-04-29
US61/048,747 2008-04-29
US61/048,756 2008-04-29
US61/048,769 2008-04-29
PCT/US2008/076707 WO2009039195A1 (fr) 2007-09-20 2008-09-17 Compositions contenant du resvératrol destinées à moduler la concentration ou l'activité d'un produit génique

Publications (2)

Publication Number Publication Date
CA2699908A1 true CA2699908A1 (fr) 2009-03-26
CA2699908C CA2699908C (fr) 2012-09-11

Family

ID=40468316

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699908A Expired - Fee Related CA2699908C (fr) 2007-09-20 2008-09-17 Compositions contenant du resveratrol destinees a moduler la concentration ou l'activite d'un produit genique

Country Status (4)

Country Link
EP (1) EP2197434A4 (fr)
JP (2) JP2010540444A (fr)
CA (1) CA2699908C (fr)
WO (1) WO2009039195A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263051B2 (en) * 2007-08-09 2012-09-11 Hallstar Innovations Corp. Photostabilization of resveratrol with alkoxycrylene compounds
JP5979810B2 (ja) * 2009-10-09 2016-08-31 株式会社山田養蜂場本社 抗老化剤
WO2011089168A2 (fr) * 2010-01-21 2011-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition particuliere pour son application comme medicament
US20120058088A1 (en) * 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
WO2013074948A1 (fr) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions contenant du resvératrol et des nucléotides
JP5608629B2 (ja) * 2011-11-28 2014-10-15 アピオン・ジャパン有限会社 サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤
WO2014043421A1 (fr) 2012-09-12 2014-03-20 Berg Llc Utilisation de marqueurs dans l'identification d'agents cardiotoxiques et dans le diagnostic et la surveillance d'une myocardiopathie et d'une maladie cardiovasculaire
CN102908338B (zh) * 2012-11-20 2014-05-14 晨光生物科技集团天津有限公司 白藜芦醇微胶囊的制备方法
US9138453B2 (en) 2013-10-14 2015-09-22 Biomarker Pharmaceuticals, Inc. Nutrient combinations for affecting an aging process
JP5933633B2 (ja) * 2014-06-18 2016-06-15 アピオン・ジャパン有限会社 サーチュイン１（ｓｉｒｔ１）遺伝子活性化剤及びテロメラーゼ逆転写酵素（ｔｅｒｔ）遺伝子活性化剤
CA2971970C (fr) * 2014-12-23 2020-04-21 Barokes Pty Ltd. Contenant pour un produit de consommation, revetu d'une couche contenant du resveratrol
WO2017096049A1 (fr) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Substances pour l'amélioration de la cathépsine b et méthodes d'utilisation
JP6272946B2 (ja) * 2016-05-20 2018-01-31 株式会社山田養蜂場本社 抗老化剤
SG11201905508VA (en) 2017-01-23 2019-08-27 Regeneron Pharma Hsd17b13 variants and uses thereof
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
WO2019075181A1 (fr) 2017-10-11 2019-04-18 Regeneron Pharmaceuticals, Inc. Inhibition de hsd17b13 dans le traitement de la maladie hépatique chez des patients exprimant la variation pnpla3 i148m
JP6411624B2 (ja) * 2017-12-26 2018-10-24 株式会社山田養蜂場本社 抗老化剤
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006298876A (ja) * 2005-04-25 2006-11-02 Saisentan Igaku Kenkyusho:Kk サーチュインの活性化剤を含む各種眼疾患治療用組成物
DK2218342T3 (en) * 2003-05-27 2018-10-22 Dsm Ip Assets Bv New nutraceutical compositions and their use
EP1648437A2 (fr) * 2003-07-01 2006-04-26 President And Fellows Of Harvard College Compositions pour la manipulation de la duree de vie et de la reaction de stress de cellules et d'organismes
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
EP1735004A4 (fr) * 2004-04-07 2011-11-09 Resveratrol Partners Llc Supplement dietetique et procede de traitement de ce dernier
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP1909910A1 (fr) * 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Dérivés de benzimidazole en tant que modulateur du sirtuin

Also Published As

Publication number Publication date
EP2197434A4 (fr) 2011-08-10
JP2010540444A (ja) 2010-12-24
JP2014058574A (ja) 2014-04-03
EP2197434A1 (fr) 2010-06-23
CA2699908C (fr) 2012-09-11
WO2009039195A1 (fr) 2009-03-26

Similar Documents

Publication Publication Date Title
CA2699908A1 (fr) Compositions contenant du resveratrol destinees a moduler la concentration ou l'activite d'un produit genique
Conney et al. Some perspectives on dietary inhibition of carcinogenesis: studies with curcumin and tea
Ronco et al. Squalene: a multi-task link in the crossroads of cancer and aging
Birringer Hormetics: dietary triggers of an adaptive stress response
Miles The uptake and distribution of coenzyme Q (10)
Conti et al. Antioxidant supplementation in the treatment of aging-associated diseases
Esrefoglu Experimental and clinical evidence of antioxidant therapy in acute pancreatitis
Keating et al. Antimetabolic effects of polyphenols in breast cancer cells: Focus on glucose uptake and metabolism
Roberto et al. Antioxidant activity of limonene on normal murine lymphocytes: relation to H2O2 modulation and cell proliferation
Dhanasekaran et al. The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus
Hsu et al. The therapeutic potential of curcumin and its related substances in turmeric: From raw material selection to application strategies
AU2017312737B2 (en) Vascular calcification and cardiovascular/associated diseases prevention and treatment
Bilecová-Rabajdová et al. Naturally occurring substances and their role in chemo-protective effects
Lv et al. Lico A enhances Nrf2‐mediated defense mechanisms against t‐BHP‐induced oxidative stress and cell death via Akt and ERK activation in RAW 264.7 cells
Leone et al. The chemopreventive role of dietary phytochemicals through gap junctional intercellular communication
Braga et al. Oral preoperative antioxidants in pancreatic surgery: a double-blind, randomized, clinical trial
Ereminas et al. Neuroprotective properties of anthocyanidin glycosides against H2O2-induced glial cell death are modulated by their different stability and antioxidant activity in vitro
Thadhani Resveratrol in management of diabetes and obesity: Clinical applications, bioavailability, and nanotherapy
Motohashi et al. Co-enzyme Q10 (ubiquinone): it’s implication in improving the life style of the elderly
Parmar et al. Antioxidants in age-related macular degeneration: Lights and shadows
Seong et al. Cancer prevention: past challenges and future directions
Hahm et al. Nutritional approaches targeting mitochondria for the prevention of sarcopenia
Gupta et al. Resveratrol: A chemo-preventative agent with diverse applications
Franco et al. Resveratrol reduces lipid peroxidation and increases sirtuin 1 expression in adult animals programmed by neonatal protein restriction
Teibo et al. Chemopreventive roles of medicinal foods against environmental carcinogens-induced cancers

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200917